Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
文献类型：期刊论文
| 作者 | Kuang, Junliang7,8; Wang, Jieyi7,8; Li, Yitao6; Li, Mengci7,8; Zhao, Mingliang7,8; Ge, Kun7,8; Zheng, Dan7,8; Cheung, Kenneth C. P.6; Liao, Boya6; Wang, Shouli7,8 |
| 刊名 | CELL METABOLISM
 |
| 出版日期 | 2023-10-03 |
| 卷号 | 35期号:10页码:1752-+ |
| ISSN号 | 1550-4131 |
| DOI | 10.1016/j.cmet.2023.07.011 |
| 通讯作者 | Jia, Weiping(wpjia@sjtu.edu.cn) ; Zheng, Xiaojiao(joyzheng99@sjtu.edu.cn) ; Jia, Wei(weijia1@hkbu.edu.hk) |
| 英文摘要 | Non-alcoholic fatty liver disease (NAFLD) is regarded as a pandemic that affects about a quarter of the global population. Recently, host-gut microbiota metabolic interactions have emerged as distinct mechanistic pathways implicated in the development of NAFLD. Here, we report that a group of gut microbiota-modified bile acids (BAs), hyodeoxycholic acid (HDCA) species, are negatively correlated with the presence and severity of NAFLD. HDCA treatment has been shown to alleviate NAFLD in multiple mouse models by inhibiting intestinal farnesoid X receptor (FXR) and upregulating hepatic CYP7B1. Additionally, HDCA significantly increased abundances of probiotic species such as Parabacteroides distasonis, which enhances lipid catabolism through fatty acid-hepatic peroxisome proliferator-activated receptor alpha (PPAR alpha) signaling, which in turn upregulates hepatic FXR. These findings suggest that HDCA has therapeutic potential for treating NAFLD, with a unique mechanism of simultaneously activating hepatic CYP7B1 and PPAR alpha. |
| WOS关键词 | OBETICHOLIC ACID ; GENE-EXPRESSION ; STEATOHEPATITIS ; MULTICENTER ; ALPHA |
| 资助项目 | National Key R&D Program of China[2022YFA0806400] ; National Key R&D Program of China[2021YFA1301300] ; National Key R&D Program of China[2019YFA0802300] ; National Natural Science Foundation of China[82270917] ; National Natural Science Foundation of China[82122012] ; National Natural Science Foundation of China[82170833] ; National Natural Science Foundation of China[82170601] ; Science and Technology Committee of Shanghai Municipality Government[23YF1432000] ; Shanghai Research Center for Endocrine and Metabolic Diseases[2022ZZ01002] |
| WOS研究方向 | Cell Biology ; Endocrinology & Metabolism |
| 语种 | 英语 |
| 出版者 | CELL PRESS |
| WOS记录号 | WOS:001088994200001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307530]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Jia, Weiping; Zheng, Xiaojiao; Jia, Wei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Southern Med Univ, Zhujiang Hosp, Microbiome Med Ctr, Dept Lab Med, Guangzhou 510655, Peoples R China 3.Southern Med Univ, Sch Basic Med Sci, Dept Pathophysiol, Guangdong Prov Key Lab Prote, Guangzhou 510515, Peoples R China 4.Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai 200032, Peoples R China 5.Tongji Univ, Sch Med, Shanghai Peoples Hosp 4, Dept Endocrinol & Metab, Shanghai 200434, Peoples R China 6.Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Peoples R China 7.Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Sch Med, Shanghai Key Lab Sleep Disordered Breathing, Shanghai 200233, Peoples R China 8.Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Ctr Translat Med, Sch Med,Shanghai Key Lab Diabet Mellitus, Shanghai 200233, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Kuang, Junliang,Wang, Jieyi,Li, Yitao,et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis[J]. CELL METABOLISM,2023,35(10):1752-+. |
| APA | Kuang, Junliang.,Wang, Jieyi.,Li, Yitao.,Li, Mengci.,Zhao, Mingliang.,...&Jia, Wei.(2023).Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis.CELL METABOLISM,35(10),1752-+. |
| MLA | Kuang, Junliang,et al."Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis".CELL METABOLISM 35.10(2023):1752-+. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。